English
+38 068 889 89 89
00380689869898 (汉语)
00380930552240 (باللغة العربية)
00380930552240 (باللغة العربية)
+38 044 223 28 95
Contact us

Our licences

The Need to Apply Hemopoietic Cell Suspensions in Patients at the Beginning of Treatment of a Cancer Disease with Complicated Progress

Smikodub A.I., Radzievskaya L.V.

Cell Therapy Clinic of National Medical University and Embryonic Tissues Center "EmCell"

Observed was a group of 20 patients aged between 35 and 81 and suffering from cancer (carcinoma of stomach in 5 cases, carcinoma of esophagus in 1 case, carcinoma of uterine cervix in 3 cases, nonhodgkin lymphomas in 2 cases, carcinoma of large intestine in 5 cases, carcinoma of gallbladder in 2 cases, and carcinoma of kidney in 2 cases). Due to various complications of malignant tumors these patients could not start the initial antitumor therapy. These complications comprised the following disorders: anemia (60% cases), leukopenia (20% cases), thrombocytopenia (20% cases), cachexia (45% cases), intoxication syndrome (50% cases), fever (30% cases). Three patients had one complication each, and remaining 17 patients had between 2 and 4 complications each. The control group comprised of 15 patients of similar age, sex, localization of the pathologic process and its complications. The objective was to provide the possibility of beginning antitumor therapy with the use of hemopoietic fetal cell suspensions (HFCS) in oncologic patients with above mentioned complications.

Transplanted were cell suspensions produced from fetal liver, in an amount of 1.5 to 3.5 ml and having high contents of stem cells (nucleated cells, 50–300x106ml; CFU-GM, 1–165x105; CFU GEMM, 2.1–9.0x105), the age of fetal cell being 8 to 12 weeks of gestation.

Assessment of transplantation effectiveness was carried out in compliance with the change of patient's general state (improvement of health, appetite, night sleep, capacity for work, gain of weight), and laboratory indices (amounts of Hb, erythrocytes, leukocytes, lymphocytes, including subpopulations of CD3+, CD4+, CD8+, CD19+, CD16+, HLA-DR).

The following results were obtained: indices of Hb and erythrocytes were restored on the 5th–30th day after transplantation; leukocytes, beginning from the 3th–7th day; thrombocytes, beginning from the 10th–20th day. During the observation period (2 months), patients suffering from cachexia gained on average 4.5±1.2 kg of weight. Patients demonstrated improvement of the general state, decrease in weakness and sweating, improvement of physical and mental activities. No side effects were noted in the course of HFCS transplantation. Immunologic blood tests carried out in the group under investigation showed an increase in the indices that characterize the antitumor resistance.

In the final account, out of 20 patients subjected to fetal stem cell treatment, 16 patients (80% cases) could start specific antitumor therapy: 7 patients began polychemotherapy; 3 patients, radiotherapy; 6 patients, surgical treatment. In the control group, only 4 patients out of 15 (26%) were able to begin specific therapy.

Better endurance of chemotherapy and radiotherapy was noted in patients that had previously received fetal cell suspensions.

Application of FCS in oncologic patients at the initial stages of a tumor disease with complicated progress permits to start the specific antitumor therapy.

Fetal stem cells treatment results depend on: disease's severity, age of the patient, adherence for the medications and regime. Treatment results, presented on this site, are individual for each clinical case.